- EMA Starts New Review of Risks with High-strength Estradiol-containing Creams
- FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma
- FDA Expands Pembrolizumab Indication for First-line Treatment of NSCLC (TPS ≥1%)
- First-line Durvalumab Improves Survival Compared to Chemotherapy in Metastatic NSCLC
- Maintenance immunotherapy fails to improve survival in extensive small cell lung cancer [ELCC Press Release]
- PROs Were Consistent with the ITT Population Across PD-L1 Subgroups in Patients with Stage III NSCLC Receiving Durvalumab or Placebo
Wolfhart Kreuz
Senior Staff Member in the Department of Paediatrics and Clinical Director of the Comprehensive Care Centre for Thrombosis and Haemostasis
Johann-Wolfgang-Goethe University Hospital in Frankfurt
Johann-Wolfgang-Goethe University Hospital in Frankfurt
Wolfhart Kreuz is a senior staff member in the Department of Paediatrics and Clinical Director of the Comprehensive Care Centre for Thrombosis and Haemostasis at Johann-Wolfgang-Goethe University Hospital in Frankfurt. He is a leader of scientific research groups engaged in haemophilia, von Willebrand disease, thrombosis, immunodeficiencies and hereditary angioedema. He is a member of several scientific societies and scientific boards and the author of numerous original publications and review articles, some of them in highly ranked journals.
Authored articles:
European Oncology & Haematology
Citation override:
European Haematology, 2008;2(1):14-20
European Oncology & Haematology
Citation override:
European Haematology Review, 2007;1(1):6-7
European Oncology & Haematology
Citation override:
European Oncology & Haematology, 2011;7(4):257-262